Document:

EX-10.29

 Exhibit 10.29 
 WAIVER, CONSENT AND OPTION TERMINATION AGREEMENT 
 This Waiver, Consent and Option
Termination Agreement (the “Agreement”) is made and entered into as of the 11th day of December, 2012 (the “Effective Date”), by and between INCLINE THERAPEUTICS,
INC., a Delaware corporation (the “Company”), and CADENCE PHARMACEUTICALS, INC., a Delaware corporation (“Cadence”). 

BACKGROUND 

A. The Company and Cadence have entered into that certain Option Agreement, effective as of June 21, 2010, as amended through the date hereof (the
“Option Agreement”), pursuant to which the Company has granted Cadence, in consideration for certain payments, an exclusive, irrevocable Option (as defined therein) to acquire the Company, subject to the terms of the Option
Agreement and the Delaware General Corporation Law. 
 B. The Company is entering into a Third Party Acquisition Agreement (as defined below)
with the Medicines Company, a Delaware corporation (“The Medicines Company”) simultaneously with the execution of this Agreement and the closing of the transactions contemplated thereby are contingent upon the termination of the
Option Agreement. 
 C. The Company desires to buy-out Cadence’s interest in, and terminate Cadence’s rights with respect to, the
Option and the Option Agreement and Cadence agrees to such buy-out and termination, on the terms and subject to the conditions set forth herein. 
 AGREEMENT 
 NOW,
THEREFORE, in consideration of the foregoing recitals and the mutual promises, representations, warranties, and covenants hereinafter set forth and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto agree as set forth herein. 
 ARTICLE 1 

CERTAIN DEFINITIONS 
 Capitalized terms used but not otherwise defined below shall have the meaning ascribed to them in the Option Agreement. In addition, the following terms used herein shall have the following meanings:

 “Buy-Out Price” means Thirteen Million One Hundred Twenty Five Thousand Dollars ($13,125,000). 

“Closing” means the consummation of a transaction pursuant to the Third Party Acquisition Agreement. 

“Parties” means Cadence and the Company, and “Party” means Cadence or the Company. 

“Third Party Acquisition Agreement” means a definitive agreement contemplating the consummation of a transaction
(whether or not a Permitted Transaction) that, if consummated, would result 

 
in The Medicines Company owning, directly or indirectly (including through beneficial ownership as described in Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended):
(a) 50% or more of the outstanding securities of any class of voting securities or voting power over voting securities, taken together as a single class (or instruments convertible into or exercisable or exchangeable for 50% or more of such
voting securities, taken together as a single class) of the Company or of the surviving entity in a merger to which the Company is party or the resulting direct or indirect parent of the Company or such surviving entity; or (b) 50% or more of
the assets of the Company. 
 “Waiver Period” means the period from the Effective Date through the earliest to
occur of (1) the date that is ninety-one (91) calendar days after the Effective Date, (b) the date on which the Third Party Acquisition Agreement is terminated by the parties thereto in accordance with its terms prior to the Closing
and (c) immediately after the Closing. 
 ARTICLE 2 

WAIVER AND TERMINATION OF OPTION AGREEMENT

 2.1 Waiver of Option; Consent to Acquisition by The Medicines Company. Subject to Section 2.5, Cadence hereby
expressly and irrevocably (a) waives and relinquishes its right to exercise the Option during the Waiver Period and (b) consents to the negotiation of and entry into a Third Party Acquisition Agreement by the Company and The Medicines
Company and the consummation of the transactions contemplated thereby, including without limitation the acquisition of the Company by The Medicines Company. 
 2.2 Termination of Option Agreement. Cadence and the Company agree that as a result of this Agreement, the Option Agreement shall be terminated pursuant to Section 4.1(a) of the Option
Agreement simultaneously with the Closing, such that the Option Agreement shall be of no further force or effect without any further action of any party and neither Cadence nor the Company will have any further rights or obligations thereunder
(except as expressly provided for herein), without any liability or obligation on the part of either of the Company or Cadence other than the payment of the Buy-Out Price. Notwithstanding the previous sentence and Section 4.2 of the Option
Agreement, the following provisions of the Option Agreement shall survive the termination of the Option Agreement and shall remain in effect: Article 1 (to the extent necessary to interpret other surviving provisions), Sections 3.2, 3.3, 3.5, and
3.7, Section 4.2, Articles 6 and Sections 7.6, 7.14 and 7.15. In addition, this Section 2.2 shall survive the termination of the Option Agreement and this Agreement. 
 2.3 Payment of Buy-Out Price. In consideration for the waiver and consent provided for in Section 2.1 and the termination of the Option Agreement pursuant to Section 2.2 of this Agreement
and Section 4.1(a) of the Option Agreement, subject to the occurrence of the Closing, the Company shall pay to Cadence the Buy-Out Price. The payment of the Buy-Out Price shall be made to Cadence in Federal or other funds immediately available
in San Diego, California, at the time of the Closing pursuant to wire instructions communicated in writing by Cadence to the Company at least three (3) days in advance of the Closing. The Company agrees that the Closing shall be contingent upon
the payment of the Buy-Out Price in accordance with such wire instructions. Any failure of the Company to pay the Buy-Out Price at the Closing to the bank account designated by Cadence in such wire instructions shall be a material breach of this
Agreement. 
 2.4 Effect on Existing Option Agreement. For clarity, except with respect to the waiver and relinquishment
by Cadence of its right to exercise the Option during the Waiver Period under Section 2.1 of this Agreement and the consent of Cadence to the entry into a Third Party Acquisition Agreement by the

  
 2. 

 
Company and The Medicines Company and the consummation of the transactions contemplated thereby (including, without limitation, the acquisition of the Company by the Medicines Company, the Option
Agreement shall remain in full force and effect until the Closing, including the rights of the Parties to terminate the Option Agreement upon any Option Termination Event set forth in Section 4.1 of the Option Agreement, it being understood and
agreed, however, that any such termination other than in connection with the Closing would not trigger any obligation on the part of the Company to pay to Cadence the Buy-Out Price. 

2.5 Effect of Failure to Close the Third Party Acquisition Agreement. Notwithstanding anything to the contrary contained herein,
the waiver, consent and termination provisions of this Article 2 shall become null and void and of no further force or effect in the event that (a) the Closing does not occur during the Waiver Period or (b) the Third Party Acquisition
Agreement is terminated by the parties thereto in accordance with its terms prior to the Closing. The Company shall provide Cadence with prompt written notice, but in any event within two calendar days, of the occurrence of either (a) or (b).

 ARTICLE 3 
 REPRESENTATIONS AND WARRANTIES 

Each of Cadence and the Company hereby represents and warrants to the other Party as follows, as of the Effective Date: 

3.1 Organization, Good Standing and Qualification. Such Party is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware. Such Party has all requisite corporate power and authority to execute and deliver this Agreement, to carry out the provisions of this Agreement, and to perform its obligations under, and carry out
the provisions of, this Agreement. Such Party is duly qualified to transact business and is in good standing in each jurisdiction where such qualification is required. 
 3.2 Authorization; Binding Obligations; Approvals. 
 (a) All corporate
actions on the part of such Party and its officers, directors and stockholders necessary for the authorization of this Agreement and the performance of all obligations of such Party hereunder have been taken. This Agreement is the valid and binding
obligation of such Party, enforceable against such Party in accordance with its terms, except as such enforcement may be limited by (i) the effect of bankruptcy, insolvency, reorganization, receivership, conservatorship, arrangement, moratorium
or other laws affecting or relating to the rights of creditors generally, or (ii) the rules governing the availability of specific performance, injunctive relief or other equitable remedies and general principles of equity, regardless of
whether considered in a proceeding in law or equity. 
 (b) No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of such Party is required in connection with the execution and delivery of this Agreement by such Party. 

3.3 Compliance with Other Instruments. The execution, delivery and performance of this Agreement and the performance by such Party
of this Agreement in accordance with its terms will not (a) violate the Certificate of Incorporation or bylaws of such Party, (b) breach or result in a violation of any law applicable to such Party, (c) constitute a material breach of
the terms, conditions, provisions of, or constitute a default under, any judgment, order, or decree of any court or arbitrator to which such Party is a party or any material contract of such Party or (d) result in the creation or imposition of
any lien, encumbrance or security interest on any of the assets or properties of such Party. 

  
 3. 

 ARTICLE 4 
 DISPUTE RESOLUTION 
 4.1 Resolution of
Disputes. The Parties agree that any disputes under this Agreement shall be governed by the dispute resolution provisions of Sections 6.1 to 6.3 of the Option Agreement. 
 4.2 Governing Law. This Agreement shall be governed by and construed under the substantive laws of the State of New York, excluding any conflicts or choice of law rule or principle that might
otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 
 4.3
Injunctive Relief. Nothing in this Article 4 or Section 5.6 will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order,
preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration or litigation if necessary to protect the interests of such Party or to preserve the status quo pending the applicable
proceeding 
 4.4 Jurisdiction. For the purposes of this Article 4, the Parties agree to accept the jurisdiction of any
U.S. District Court located in California for the purposes of enforcing any awards entered into pursuant to this Agreement or for the litigation of any claim or in seeking any injunction under this Article 4 and for enforcing the agreements
reflected in this Article 4. 
 ARTICLE 5 
 GENERAL PROVISIONS 
 5.1 Notices. Any
notice or other communication required or permitted to be delivered to either Party under this Agreement shall be in writing and shall be deemed properly delivered, given and received when delivered (by hand, by courier or express delivery service
or by facsimile) to the address or facsimile telephone number set forth beneath the name of such Party below (or to such other address or facsimile telephone number as such Party shall have specified in a written notice given to the other Party).

 if to Cadence: 
 12481 High Bluff Drive, Suite 200 
 San Diego, CA 92130 

Attn: General Counsel 
 Facsimile: 
 with a copy to (which shall not constitute notice): 

Latham & Watkins LLP 
 12636 High Bluff Drive, Suite 400 
 San Diego, CA 92130 

Attn: Faye H. Russell, Esq. 
          Cheston J. Larson, Esq. 

Facsimile: 

  
 4. 

 if to the Company: 

900 Saginaw Drive 

Suite 200 

Redwood City, CA 94063 
 Attn: Alan Levy, CEO 
 Facsimile: 

with a copy to (which shall not constitute notice): 
 Cooley LLP 
 3000 El Camino Real 

Five Palo Alto Square 
 Palo Alto, CA 94306 
 Attn: Barbara A. Kosacz 

Facsimile: 

5.2 Severability. If any term or other provision of this Agreement is held to be invalid, illegal or incapable of being enforced
by any rule of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is
invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term
or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the
power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other
purposes of such invalid or unenforceable term. 
 5.3 Entire Agreement. Except as expressly set forth herein, including
with respect to the waiver of the exercise of the Option by Cadence, the consent by Cadence to the negotiation of and entry into a Third Party Acquisition Agreement by the Company and the Medicines Company and the termination of the Option and the
Option Agreement, nothing in this Agreement is intended to amend or modify the Option Agreement. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter herein. 

5.4 Successors and Assigns; Assignment. This Agreement shall be binding upon the Company and its permitted successors and
permitted assigns (if any) and Cadence and its successors and permitted assigns (if any). This Agreement shall inure to the benefit of the Company, Cadence and the respective successors and assigns (if any) of the foregoing. This Agreement shall not
be assigned by either Party, whether by operation of law or otherwise; in whole or in part, without obtaining the prior written consent or approval of the other Party. This Agreement may be assigned by Cadence whether by operation of law or
otherwise; in whole or in part, to any successor to all or substantially all of the business of Cadence, whether by merger, acquisition of assets or otherwise without the consent of the Company; provided that the Option Agreement is also so
assigned. 
 5.5 Parties in Interest. Nothing in this Agreement, express or implied, is intended to or shall confer upon
any other Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, except with respect to the consent provided by Cadence in Section 2.1, which is for the benefit of and shall be enforceable by The
Medicines Company. 

  
 5. 

 5.6 Enforcement of Agreement. The Parties hereto agree that irreparable damage would
occur to the Parties if any of the provisions of this Agreement, including the provisions of Article 4, were not performed in accordance with its specific terms or were otherwise breached. It is accordingly agreed that the Parties would not have an
adequate remedy at law and therefore will be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, this being in addition to any other remedy to which the Parties
are entitled hereunder, at law or in equity. 
 5.7 Headings. The descriptive headings contained in this Agreement are
included for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement. 

5.8 Counterparts. This Agreement may be executed and delivered (including by facsimile transmission) in one or more counterparts,
and by the different Parties in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. 

5.9 Waiver. No failure on the part of either Party to exercise any power, right, privilege or remedy under this Agreement, and no
delay on the part of either Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or
remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. Neither Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this
Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party; and any such waiver shall not be applicable or have any effect except
in the specific instance in which it is given. 
 5.10 Further Assurances. Each Party hereto shall execute and cause to
be delivered to the other Party hereto such instruments and other documents, and shall take such other actions, as such other Party may reasonably request for the purpose of carrying out this Agreement. 

5.11 Construction. For purposes of this Agreement, whenever the context requires the singular number shall include the plural, and
vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. 

(a) The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall
not be applied in the construction or interpretation of this Agreement. 
 (b) As used in this Agreement, the words
“include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” 

(c) Except as otherwise indicated, (i) all references in this Agreement to “Articles” and “Sections” are
intended to refer to Articles or Sections of this Agreement, and (ii) all references in this Agreement to dollar amounts are intended to refer to U.S. dollars. 
 5.12 Amendment and Waiver. This Agreement may not be amended, modified, altered or supplemented other than by means of a written instrument duly executed and delivered on behalf of Cadence and the
Company. 

  
 6. 

 IN WITNESS WHEREOF, the Parties have caused this Waiver and Option Termination Agreement to be executed and
delivered as of the 11th day of December, 2012. 
  

			
	CADENCE PHARMACEUTICALS, INC.
		
	Signature:	 	 /s/ Theodore R. Schroeder

	Name:	 	Theodore R. Schroeder
	Title:	 	President and Chief Executive Officer
	
	INCLINE THERAPEUTICS, INC.
		
	Signature:	 	 /s/ David Socks

	Name:	 	David Socks
	Title:	 	President and Chief Operating OfficerEX-10.30

 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 Exhibit
10.30 
 SETTLEMENT AGREEMENT 
 This Settlement Agreement (including Exhibit A, this “Settlement Agreement”) is made and entered into, as of November 27, 2012, by and between, on the one hand, Cadence Pharmaceuticals,
Inc., a corporation organized under the laws of Delaware (“Cadence”), and SCR Pharmatop, a civil law partnership organized and existing under the laws of France (“Pharmatop” and, together with Cadence, the “Cadence
Parties”), and, on the other hand, Paddock Laboratories, LLC, a limited liability company formed under the laws of Delaware (“Paddock LLC”), and Perrigo Company, a corporation organized under the laws of Michigan (“Perrigo”
and, together with Paddock LLC, the “Paddock Parties”). Each of the Cadence Parties and Paddock Parties is referred to as a “Party” and, collectively, as the “Parties”. 

RECITALS 
 WHEREAS, Pharmatop owns, Cadence is the exclusive sub-licensee of, and the Cadence Parties have the right to enforce, U.S. Patent Nos. 6,028,222 (“the ’222 Patent”) and 6,992,218 (“the
’218 Patent”), which are listed in the U.S. Food and Drug Administration’s (“US FDA”) publication, Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the “Orange Book”), in
connection with approved New Drug Application (“NDA”) No. 022450 for the drug formulation
OFIRMEV® (injectable acetaminophen) 10 mg/mL, 100 mL vials (“Cadence Product”), which product Cadence
has sold or sells in the United States of America; 
 WHEREAS, Paddock [Laboratories, Inc., the assets and liabilities of which
have since been transferred to Paddock LLC (“Paddock Inc.” and, together with Paddock LLC, “Paddock”),] notified Cadence that it had submitted Abbreviated New Drug Application (“ANDA”) No. 202605 to the US FDA
under Section 505(j)(2)(B) of the Food, Drug and Cosmetic Act, seeking the US FDA’s approval to manufacture, use and sell an injectable acetaminophen drug product in the United States of America as a generic version of Cadence’s
Product (“Paddock’s Product”) prior to expiration of the ’218 Patent and the ’222 Patent (“Paddock ANDA”); 
 WHEREAS, Cadence commenced a civil action against Paddock before the United States District Court for the District of Delaware (“District Court”), Cadence Pharmaceuticals, Inc. & SCR
Pharmatop v. Paddock Laboratories, Inc. et al., No. 1:11-cv-00733-LPS, alleging, inter alia, that the filing of the Paddock ANDA constituted an act of infringement under 35 U.S.C. § 271(e)(2)(A) of the ’218 Patent and
the ’222 Patent (“Pending Litigation”); and 
 WHEREAS, the Parties are willing to settle the Pending Litigation
on the terms set forth herein and in a License Agreement (as defined below), in an effort to avoid further litigation and contain associated fees, costs, and expenses. 

 NOW, THEREFORE, in consideration of the mutual covenants set forth herein and in the License
Agreement, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 1. Definitions. All capitalized
terms used, but not otherwise defined herein, shall have the meanings set forth in the License Agreement (defined below). As used herein, the following capitalized terms shall have the meanings ascribed to them below: 

“Commercially Reasonable Efforts” means the reasonable, diligent, and good-faith efforts as a Party would
normally use to accomplish a similar objective under similar circumstances. 
 “Effective Date”
means the date on which the District Court has entered a Stipulation and Order of Dismissal in the Pending Litigation, and all orders, decisions and finding underlying such final judgment are merged therein. 

“Execution Date” means the date on which all the Parties have executed this Settlement Agreement.

 “License Agreement” means the License Agreement, between the Parties hereto, attached to this
Settlement Agreement as Exhibit B. 
 “Pending Claims” means all claims asserted in, arising out
of, or relating to the Pending Litigation. 
 “Person” means an individual, partnership,
corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture, governmental authority, or other entity of whatever nature. 
 2. Antitrust Review. 
 (a) As soon as practicable and in no
event later than [***] following the Execution Date, the Parties shall submit this Settlement Agreement and the License Agreement to the appropriate personnel at the United States Federal Trade Commission and Antitrust Division of United
States Department of Justice (“Agencies”) for review under Section 1112 of the Medicare Prescription Drug Improvement and Modernization Act of 2003. Each Party shall notify the other Parties when it has submitted this Settlement
Agreement to the Agencies. 
 (b) If, within [***] of receipt of this Settlement Agreement by the
Agencies, any Agency objects to, responds to, or otherwise comments on such submission, or requests information concerning such submission, the Parties shall use Commercially Reasonable Efforts to address or resolve such objection, response or
comment and respond to such request for information; provided, however, that such Commercially 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 2 

 
Reasonable Efforts shall not result in a material change to the rights and obligations of the Parties under this Settlement Agreement and the License Agreement, except as the Parties may
otherwise mutually agree in writing. Such Commercially Reasonable Efforts to address or resolve any such objection, response or comment or respond to such request shall continue for a period of not more than [***] from when the objection,
response or comment is first raised or the request is first made, unless the Parties mutually agree in writing to extend such [***] period. During such [***] or agreed extension thereof, all obligations under this Settlement Agreement
and the License Agreement shall be temporarily suspended while the Parties engage in commercially reasonable and good-faith efforts to address or resolve any such objection, response or comment, or to respond to such request, by any such Agency. If,
despite such Commercially Reasonable Efforts, either Party concludes that the Parties are unable to adequately address or resolve any such objection, response or comment, or to respond to such request for information during such [***] period
or agreed extension thereof, the Parties shall, unless they agree otherwise in writing, promptly reinstate the Pending Litigation. In the event of such reinstatement, the Parties shall use Commercially Reasonable Efforts to return the Parties to the
position they were in before signing this Settlement Agreement; and the Paddock Parties shall not challenge the applicability or reinstatement of the full balance of any stay of US FDA approval existing as of the Execution Date as to which the
Paddock ANDA would have been subject but for the execution of this Settlement Agreement and the License Agreement, and, in the event the stay cannot be reinstated, each of the Paddock Parties hereby consent to the entry of a preliminary injunction
prohibiting any of the Paddock Parties from manufacture or sale of Paddock’s Product for the full balance of any time the stay existing as of the Execution Date would have been in effect, but for the execution of this Settlement Agreement and
the License Agreement. None of the Paddock Parties shall market Paddock’s Product prior to the date on which any such stay existing as of the Execution Date would have expired but for the execution of the Settlement Documents and entry of the
Litigation Stay. Upon accomplishing such reinstatement, this Settlement Agreement and the License Agreement shall terminate and shall be void ab initio. 
 3. Stipulation to Order of Dismissal. In consideration of the mutual benefits of entering into this Settlement Agreement, the Parties shall enter into and cause to be filed with the District Court,
within [***] after the Execution Date, a stipulation and proposed order dismissing with prejudice all claims, defenses and counterclaims as between the Cadence Parties and the Paddock Parties in the Pending Litigation, substantially in the
form annexed hereto as Exhibit A (“Stipulation and Order of Dismissal With Prejudice”). If the District Court raises an objection to, or does not grant, the Stipulation and Order of Dismissal With Prejudice in substantially the same form
as that annexed hereto as Exhibit A, the Parties shall confer in good faith and revise the Stipulation and Order of Dismissal With Prejudice consistent with the requirements of the District Court and this Settlement Agreement and License Agreement.
The Parties agree that this Settlement Agreement (except for Sections 1 and 2 hereof) and the License Agreement (collectively, the “Settlement Documents”) shall not become effective, and shall not be binding on any such Party and shall not
have any force or effect, until the Effective Date. In the event 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 3 

 
that an order dismissing the Pending Litigation with prejudice is not entered within [***] from the date the Stipulation and Order of Dismissal With Prejudice was first submitted to the
District Court (or by such later date as the Parties may mutually agree in writing), the Settlement Documents shall terminate and shall be void ab initio. 
 4. Settlement and Release. From the Effective Date, the Parties agree as follows: 
 (a) The Cadence Parties, on behalf of themselves and their respective Affiliates, hereby release, acquit, and discharge the Paddock Parties and their respective Affiliates from all Pending Claims. The
foregoing release discharge covers all of such Pending Claims, from the beginning of time through and including the Effective Date. 
 (b) The Paddock Parties, on behalf of themselves and their respective Affiliates, hereby release, acquit, and discharge the Cadence Parties and their respective Affiliates from all Pending Claims. The
foregoing release covers all of such Pending Claims, from the beginning of time through and including the Effective Date. 
 5. Scope of
Settlement and Release. Notwithstanding anything to the contrary elsewhere in Sections 3 and 4, nothing in this Settlement Agreement is intended to prevent or preclude any of the Parties (a) from participating in (including, without
limitation, initiating) future proceedings that bear upon or relate to (i) the Parties’ respective obligations or rights under this Settlement Agreement and/or the License Agreement, including, without limitation, post-Effective Date
treatment or resolution of issues related to and/or the enforcement of this Settlement Agreement and/or the License Agreement, or (ii) subject to Section 4.6 of the License Agreement, claims that are unrelated to either the Pending
Litigation or Paddock’s Product, or (b) from invoking the continuing jurisdiction of the District Court to enforce this Settlement Agreement and/or the License Agreement. 
 6. Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Parties as follows: 

(a) that such Party has obtained the advice of legal counsel prior to such Party’s execution and delivery of the
Settlement Documents, and that such Party’s execution and delivery of this Settlement Agreement containing the releases set forth above are made voluntarily, with full knowledge of their significance, and with the express intention of
extinguishing all obligations; 
 (b) the Settlement Documents have been duly executed and delivered and
constitute the legal, valid, and binding obligations of such Party, enforceable in accordance with their terms; 

(c) the execution, delivery, and performance of the Settlement Documents do not and will not violate or conflict with any
provision of such Party’s Certificate of Incorporation or bylaws, or other operating or partnership agreement, as applicable and in effect on the Execution Date; 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 4 

 (d) that such Party: (i) has read the Settlement Documents,
(ii) fully understands all the terms and conditions thereof and the meaning of each provision thereof (including specifically the releases and covenants contained herein), and (iii) has entered into the Settlement Documents of its own free
will and volition, has been advised to consult counsel, has had the opportunity to consult with counsel concerning the Settlement Documents, and freely and voluntarily enters into them; and 

(e) the Settlement Documents were negotiated by the Parties on an arm’s-length basis. 

7. Acknowledgements, Settlement Agreements and Covenants. The Parties consent to the jurisdiction and venue of the District Court for the purposes
of the settlement of the Pending Litigation and enforcement of the terms of the Settlement Documents. The Parties acknowledge and agree that any breach of the License Agreement shall constitute a breach of this Settlement Agreement. Subject to the
terms of the License Agreement, the Paddock Parties acknowledge and admit that, in the absence of the License Agreement, the making, using, selling, offering for sale, or importing of the Paddock Product would infringe the claims of the ’218
Patent and the ’222 Patent, that the filing of the Paddock ANDA No. 202605 was a technical act of infringement with respect to the ’218 Patent and the ’222 Patent, and that the claims of the ’218 Patent and the ’222
Patent are valid and enforceable. 
 8. Confidentiality. The terms of the Settlement Documents and the negotiations of the Parties
pertaining thereto shall be maintained in confidence by the Parties except as is: (i) required by statute, ordinance or regulation, including, without limitation, SEC reporting requirements, or by the rules or regulations of any stock exchange
that a Party is subject to; (ii) required pursuant to compulsory legal process or by discovery obligations incident to litigation; (iii) necessary for the exercise of the rights granted to the Parties under the Settlement Documents,
including that the Paddock Parties may disclose such terms to the US FDA as may be reasonably necessary in obtaining and maintaining final approval of the Paddock ANDA and launching Paddock’s Product that is the subject of the Paddock ANDA,
when and only when as provided by the License Agreement; (iv) expressly provided in this Settlement Agreement; or (v) expressly permitted under this Section 8, or as otherwise agreed to in writing by the Parties. 

(a) If a Party is disclosing information relating to the Settlement Documents because it is required to do so to comply
with statutory, regulatory, or legal process requirements, including its reporting requirements under the SEC rules, or any national securities exchange on which it is listed, such Party intending to make such disclosure shall give the other Parties
at least [***] prior notice in writing of the text of the intended disclosure, unless such statutory, regulatory, or legal process requirements would require earlier disclosure, in which event, the notice shall be provided as early as
practicable. 
 (b) Such disclosing Party shall request confidential treatment with respect to the terms of the
Settlement Documents and to use commercially reasonable efforts to have redacted such provisions of the Settlement Documents as the Parties may agree 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 5 

 
from any copies filed pursuant to such statutory, regulatory, or legal process requirements. Without limiting the generality of the foregoing, if a Party determines that it will be required to
file the Settlement Documents as provided above, promptly after the giving of notice by such Party as contemplated above, the Parties shall use Commercially Reasonable Efforts to agree on those provisions of the Settlement Documents that the Parties
will seek to have redacted as provided above. 
 (c) Each Party may disclose the terms of the Settlement
Documents to its respective Affiliates, insurers, lenders, attorneys, and accountants, subject to such Affiliates, insurers, lenders, attorneys, accountants, and potential investors, acquirors or merger partners, being bound by confidentiality
obligations. 
 9. Public Documents. The Parties recognize that, once it is filed with the District Court, the Stipulation and Order of
Dismissal With Prejudice will be a matter of public record and therefore will not be subject to any confidentiality restrictions herein. The Parties also recognize that, upon the filing of the Stipulation and Order of Dismissal With Prejudice with
the District Court, the fact that the Parties have settled the Pending Litigation will be a matter of public record and thus will not be subject to any confidentiality restrictions herein; provided, however, that, subject to the terms of the License
Agreement, the terms of such settlement shall be maintained in confidence as provided by Section 8 above. 
 10. Press Release.
Notwithstanding the foregoing, after the District Court grants dismissal of the Pending Litigation, any Party may, without prior written approval, announce that the Parties have entered into settlement and license agreements. Except as permitted
hereunder or under the License Agreement, the terms of such settlement and license agreements shall remain confidential. 
 11. General
Provisions. 
 (a) The Settlement Documents contain the entire settlement terms pertaining to the subject matter hereof, and
supersede any prior or contemporaneous negotiations, representations, settlement agreements, and understandings of the Parties with respect to such subject matter, whether written or oral. The Parties acknowledge that they have not relied on any
promise, representation, or warranty, expressed or implied, not contained in the Settlement Documents. 
 (b) This Settlement
Agreement is the result of good faith negotiations and compromise. The Settlement Agreement and the releases contained in this Settlement Agreement affect the Pending Claims, and, except as expressly set forth in this Settlement Agreement, nothing
set forth herein shall be construed as an admission by any Party hereto of any liability of any kind to the other, or to any other Person. 
 (c) Each of the Parties covenants and agrees, severally and for itself and its Affiliates only, to take additional actions that may be reasonably necessary or appropriate to fully effectuate the terms,
intent, and conditions of this Settlement Agreement. 

  
 6 

 (d) This Settlement Agreement shall inure to the benefit of the Parties and shall be binding
upon the Parties and their respective successors and permitted assigns. 
 (e) Each Party acknowledges and agrees that money
damages would not be a sufficient remedy for any breach of this Settlement Agreement or the License Agreement by another Party, as the case may be, and that the non-breaching Party or Parties will be entitled to equitable relief, including a
temporary restraint, a preliminary injunction, a permanent injunction, and specific performance for any such breach. Such remedies are not to be the exclusive remedies for a breach of this Settlement Agreement or the License Agreement, but will be
in addition to all other remedies available at law or equity. 
 (f) This Settlement Agreement will be deemed to have been
drafted jointly by the Parties and therefore no provision of this Settlement Agreement shall be construed against any Party on the theory that a particular Party drafted such provision. 

(g) This Settlement Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving
effect to any choice or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than the State of Delaware. All actions and proceedings arising out of or relating to this Settlement Agreement or the
License Agreement shall be heard and determined exclusively in the District Court, and each Party irrevocably waives, and agrees not to assert by way of motion, defense, or otherwise, in any such action or proceeding, any claim that it is not
subject personally to the jurisdiction of the District Court, that its property is exempt or immune from attachment or execution, that such action or proceeding is brought in an inconvenient forum, that the venue of such action or proceeding is
improper, or that this Settlement Agreement or the License Agreement or the transactions contemplated hereby or thereby may not be enforced in or by the District Court. In the event that the District Court lacks subject-matter jurisdiction, the
provisions of this paragraph apply equally to the Delaware state courts. 
 (h) This Settlement Agreement may be executed
simultaneously in any number of counterparts, and sent via facsimile or e-mail to the other Parties, each of which when so executed and delivered shall be taken to be an original, but such counterparts shall together constitute but one and the same
document. Telefacsimile or e-mail transmissions of any executed original counterpart signature page to this Settlement Agreement and/or retransmission of any such executed telefacsimile or e-mail transmission shall be deemed to be the same as the
delivery of an executed original and the Parties may not claim any defect based upon another Party’s inability to produce a “hard” signature copy. At the request of a Party, a Party shall confirm fax transmissions by executing
duplicate original documents and delivering the same to the requesting Party. 
 (i) Headings in this Settlement Agreement are
for convenience of reference only and shall not affect its interpretation or construction. 

  
 7 

 (j) Each Party shall bear its own costs, fees, and expenses in any way related to the
negotiation, preparation, execution, and delivery of this Settlement Agreement and the obligations and releases contained herein. 
 (k) Assignment of this Settlement Agreement is subject to the same terms and conditions as the assignment of the License Agreement, and this Settlement Agreement may be assigned only in connection with
(and to the assignee of) an assignment of the License Agreement. Notwithstanding anything in this Settlement Agreement to the contrary, assignment of this Settlement Agreement shall not release any claims against a Person that is not a Party or an
Affiliate of a Party on the Execution Date. 
 (l) As used in this Settlement Agreement, neutral pronouns and any variations
thereof shall be deemed to include the feminine and masculine and all terms used in the singular shall be deemed to include the plural, and vice versa, as the context may require. The words “herein,” “hereof” and
“hereunder” and other words of similar import refer to this Settlement Agreement as a whole, as the same may from time to time be amended or supplemented, and not to any particular subdivision contained in this Settlement Agreement. The
word “including” when used herein is not intended to be exclusive, or to limit the generality of the preceding words, and means “including, without limitation”. Where a Party’s consent is required hereunder, except as
otherwise specified herein, such Party’s consent may be granted or withheld in such Party’s sole discretion. 
 12. Notices.
All notices pursuant to this Settlement Agreement shall be provided, by (a) fax or e-mail, followed by sending a copy by first class mail or express delivery service, and (b) first class mail or express delivery service, as follows and
shall be deemed effective upon receipt of same: 
 If to the Cadence Parties: 

Cadence Pharmaceuticals, Inc. 
 12481 High Bluff Drive, Suite 200 
 San Diego, California 92130 

Attention: General Counsel 
 Phone: [***] 
 Fax: [***] 

Email: [***] 
 and

 Kenneth Schuler 
 Latham & Watkins 
 233 South Wacker Drive, Suite 5800 

Chicago, IL 60606 

Phone: [***] 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 8 

 Fax: [***] 
 Email: [***] 
 and 
 SCR Pharmatop 
 10, Square St. Florentin 

78150 Le Chesnay, France 
 Attention: Managing Director 
 Phone: [***] 

Fax: [***] 

Email: [***] 
 and

 Didier Ravaud 
 SCP Ayme Ravaud Leguen 
 10 rue Cimarosa 75116 

Paris, France 

Phone: [***] 
 Fax: [***] 
 Email: [***] 

and 
 Charles Weiss 

Holland & Knight LLP 
 31 West 52nd Street 
 New York NY 10019 

Phone: [***] 
 Fax: [***] 
 Email: [***] 

and 
 Thomas C. Grimm

 Morris, Nichols, Arsht & Tunnell LLP 
 1201 North Market Street 
 P.O. Box 1347 

Wilmington, DE 19899-1347 
 Phone: [***] 
 Fax: [***] 

Email: [***] 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 9 

 If to the Paddock Parties: 
 Paddock Laboratories, LLC 
 c/o Perrigo Company 

515 Eastern Avenue 
 Allegan, MI 49010 
 Attention: General Counsel 

Phone: [***] 
 Fax: [***] 
 Email: [***] 

and 
 Perrigo Company

 515 Eastern Avenue 
 Allegan, MI 49010 
 Attention: General Counsel 

Phone: [***] 
 Fax: [***] 
 Email: [***] 

and 
 Jeffrey S. Ward

 Merchant & Gould P.C. 
 10 East Doty Street, Suite 600 
 Madison, WI 53703 

Phone: [***] 
 Fax: [***] 
 Email: [***] 

[Signature Page Follows] 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
 10 

 IN WITNESS WHEREOF, the Parties hereto have each caused this Settlement Agreement to be
executed by their authorized representatives as of the Execution Date. 
  

			
	Cadence Pharmaceuticals, Inc.
		
	By	 	 /s/ Theodore R. Schroeder

		
	Name:	 	Theodore R. Schroeder
		
	Title:	 	President and CEO
	
	SCR Pharmatop
		
	By	 	 /s/ Dietlin

		
	Name:	 	Dietlin
		
	Title:	 	General Manager
	
	Paddock Laboratories, LLC
		
	By	 	 /s/ Sharon Kochan

		
	Name:	 	Sharon Kochan
		
	Title:	 	EVP
	
	Perrigo Company
		
	By	 	 /s/ Ronald Winowiecki

		
	Name:	 	Ronald Winowiecki
		
	Title:	 	Treasurer

  
 11 

 EXHIBIT A 
 Stipulation and Order of Dismissal With Prejudice 

 UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF DELAWARE 
  

					
	 	 	)	    	
	CADENCE PHARMACEUTICALS, INC.	 	)	    	
	AND SCR PHARMATOP,	 	)	    	
		 	)	    	
	 Plaintiffs,
	 	)	    	
		 	)	    	C.A. No. 11-733-LPS
	v.	 	)	    	
		 	)	    	
	PADDOCK LABORATORIES, INC.;	 	)	    	
	PERRIGO COMPANY; PADDOCK	 	)	    	
	LABORATORIES, LLC; EXELA PHARMA	 	)	    	
	SCIENCES, LLC; EXELA PHARMSCI, INC.;	 	)	    	
	and EXELA HOLDINGS, INC;	 	)	    	
		 	)	    	
	 Defendants.
	 	)	    	

 STIPULATION TO ORDER OF DISMISSAL 

PURSUANT TO FED. R. CIV. P. 41(a)(2) 
 Pursuant to Rule 41(a)(2) of the FEDERAL RULES OF CIVIL PROCEDURE, the Plaintiffs, Cadence Pharmaceuticals, Inc. and SCR
Pharmatop, and Defendants Perrigo Company, Paddock Laboratories, Inc., and Paddock Laboratories, LLC (collectively “the Parties”) hereby stipulate to the entry of the attached proposed Order of Dismissal, dismissing with prejudice all
claims, counterclaims, and defenses as between the Parties, with the Parties bearing their own costs. 

					
	MORRIS, NICHOLS, ARSHT & TUNNELL LLP	 		 	POTTER ANDERSON & CORROON LLP
	  
	 		 	  

	 Jack B. Blumenfeld, Esq.

Thomas C. Grimm, Esq.
 1201 North Market
Street
 P.O. Box 1347
 Wilmington, DE
19899
  
 Attorneys for Plaintiffs

Cadence Pharmaceuticals, Inc.
 and SCR
Pharmatop
	 		 	 Richard L. Horwitz, Esq.
 David
E. Moore, Esq.
 Hercules Plaza, 6th Floor
 1313
N. Market Street
 Wilmington, DE 19801
  

Attorneys for Defendants
 Perrigo Company,
Paddock Laboratories,
 Inc., and Paddock Laboratories, LLC.

	  
 OF COUNSEL:

 
 LATHAM & WATKINS LLP
	 		 	  
 OF COUNSEL:

 
 MERCHANT & GOULD P.C.

	 Kenneth G. Schuler, Esq.
 233
S. Wacker, Suite 5800
 Chicago, Illinois 60606
 Telephone No.: [***]
  

Attorneys for Plaintiff
 Cadence Pharmaceuticals,
Inc.
  
 HOLLAND & KNIGHT LLP

Charles A. Weiss, Esq.
 31 West 52nd
Street
 New York, NY 10019
 Telephone
No.: [***]
  
 Attorneys for Plaintiff

SCR Pharmatop
	 		 	 Jeffrey S. Ward, Esq.
 10 East
Doty Street, Suite 600
 Madison, WI 53703
 Telephone No. [***]
  

Attorneys for Defendants
 Perrigo Company,
Paddock Laboratories,
 Inc., and Paddock Laboratories, Inc.

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF DELAWARE 
  

					
	 	 	)	    	
	CADENCE PHARMACEUTICALS, INC.	 	)	    	
	AND SCR PHARMATOP,	 	)	    	
		 	)	    	
	 Plaintiffs,
	 	)	    	
		 	)	    	C.A. No. 11-733-LPS
	v.	 	)	    	
		 	)	    	
	PADDOCK LABORATORIES, INC.;	 	)	    	
	PERRIGO COMPANY; PADDOCK	 	)	    	
	LABORATORIES, LLC; EXELA PHARMA	 	)	    	
	SCIENCES, LLC; EXELA PHARMSCI, INC.;	 	)	    	
	and EXELA HOLDINGS, INC.;	 	)	    	
		 	)	    	
	 Defendants.
	 	)	    	

 [Proposed] ORDER OF DISMISSAL 

Pursuant to Rule 41(a)(2) of the FEDERAL RULES OF CIVIL
PROCEDURE, and pursuant to and based on the stipulation of Plaintiffs, Cadence Pharmaceuticals, Inc. and SCR Pharmatop, and Defendants Perrigo Company, Paddock Laboratories, Inc. and Paddock Laboratories, LLC (collectively “the
Parties”), it is hereby ORDERED that all claims, counterclaims and defenses as between the Parties, are dismissed with prejudice. The Parties shall bear their own costs. 
 SO ORDERED: 
 This      day of
            , 2012 
  

	
	  

	Honorable Leonard Stark
	United States District Court Judge

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]